The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Clinical significance of the sparteine/debrisoquine oxidation polymorphism
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183
The P450 Gene Superfamily: Recommended Nomenclature
NEBERT, D. W., ADESNIK, M., COON, M. J., ESTABROOK, R. W., GONZALEZ, F. J., GUENGERICH, F. P., GUNSALUS, I. C., JOHNSON, E. F., KEMPER, B., LEVIN, W., et al. (1987) · DNA · doi:10.1089/dna.1987.6.1 · Cited by 818
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
Gonzalez, F. J., Skodat, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. V., Hardwick, J. P., & Meyer, U. A. (1988) · Nature · doi:10.1038/331442a0 · Cited by 715
Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
Eichelbaum, M., Spannbrucker, N., Steincke, B., & Dengler, H. J. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562059 · Cited by 632
Cloning of the cDNA for the human beta 1-adrenergic receptor.
Frielle, T., Collins, S., Daniel, K. W., Caron, M. G., Lefkowitz, R. J., & Kobilka, B. K. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.22.7920 · Cited by 575
Evans, D. A., Mahgoub, A., Sloan, T. P., Idle, J. R., & Smith, R. L. (1980) · Journal of Medical Genetics · doi:10.1136/jmg.17.2.102 · Cited by 536
Kronbach, T., Fischer, V., & Meyer, U. A. (1988) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1988.87 · Cited by 533
Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R., & Branch, R. A. (1985) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1985.194 · Cited by 452
Schmid, B., Bircher, J., Preisig, R., & Küpfer, A. (1985) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1985.235 · Cited by 383
Discombe, G. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91898-4 · Cited by 376
Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
K�pfer, A., & Preisig, R. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541938 · Cited by 362
Frontiers in Biochemical and Pharmacological Research in Depression
Usdin, E. (1984) · Medical Entomology and Zoology · Cited by 278
Bertilsson, L., Henthorn, T. K., Sanz, E., Tybring, G., Säwe, J., & Villén, T. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.40 · Cited by 249
Otton, S. V., Inaba, T., & Kalow, W. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90332-1 · Cited by 186
Inaba, T., Jurima, M., Mahon, W. A., & Kalow, W. (1985) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08231-5 · Cited by 179
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings
Dahl-Puustinen, M.-L., Lidén, A., Alm, C., Nordin, C., & Bertilsson, L. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.109 · Cited by 164
Ethnic Differences in Reactions to Drugs and Xenobiotics
Roberts, D. F. (1987) · Journal of Medical Genetics · doi:10.1136/jmg.24.9.574-b · Cited by 156
Plasma Level Monitoring of Antipsychotic Drugs Clinical Utility
Dahl, S. G. (1986) · Clinical Pharmacokinetics · doi:10.2165/00003088-198611010-00003 · Cited by 147
Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man
Zanger, U. M., Vilbois, F., Hardwick, J. P., & Meyer, U. (1988) · Biochemistry · doi:10.1021/bi00415a010 · Cited by 146
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects
Steiner, E., Bertilsson, L., Säwe, J., Bertling, I., & Sjöqvist, F. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.176 · Cited by 133
Polymorphism of carbon oxidation of drugs and clinical implications.
Sloan, T. P., Mahgoub, A., Lancaster, R., Idle, J. R., & Smith, R. L. (1978) · BMJ · doi:10.1136/bmj.2.6138.655 · Cited by 116
Fonné‐Pfister, R., & Meyer, U. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90063-9 · Cited by 116
Br�sen, K., Klysner, R., Gram, L. F., Otton, S. V., Bech, P., & Bertilsson, L. (1986) · European Journal of Clinical Pharmacology · doi:10.1007/bf00608215 · Cited by 102
Self-citationImipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype
Brøsen, K., Otton, S. V., & Gram, L. F. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.221 · Cited by 100
Self-citationKroemer, H. K., Mikus, G., Kronbach, T., Meyer, U., & Eichelbaum, M. F. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.5 · Cited by 86
Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation
Kupfer, A., & Branch, R. A. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.196 · Cited by 86
First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype
Brøsen, K., & Gram, L. F. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.50 · Cited by 86
Self-citationKnodell, R. G., Dubey, R. K., Wilkinson, G. R., et al. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24109-x · Cited by 82
Bovine and Human cDNA Sequences Encoding a Putative Benzodiazepine Receptor Ligand
Webb, N. R., Rose, T. M., MALIK, N., Marquardt, H., SHOYAB, M., Todaro, G. J., & Lee, D. C. (1987) · DNA · doi:10.1089/dna.1987.6.71 · Cited by 72
Influence of the defective metabolism of sparteine on its pharmacokinetics
Eichelbaum, M. F., Spannbrucker, N., & Dengler, H. J. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562060 · Cited by 66
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.
Jackson, P., Tucker, G., Lennard, M., & Woods, H. (1986) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1986.tb02933.x · Cited by 66
Boobis, A. R., Murray, S., Kahn, G. C., et al. (1983) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14267-3 · Cited by 66
Influence of oxidation polymorphism on phenformin kinetics and dynamics
Oates, N. S., Shah, R. R., Idle, J. R., & Smith, R. L. (1983) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1983.257 · Cited by 62
Baumann, P., Jonzier-Perey, M., Koeb, L., et al. (1986) · International Clinical Psychopharmacology · doi:10.1097/00004850-198604000-00002 · Cited by 60
Genetically determined oxidation capacity and the disposition of debrisoquine.
Sloan, T. P., Lancaster, R., Shah, R., et al. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb01528.x · Cited by 59
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine
Mikus, G., Ha, H. R., Vožeh, S., Zekorn, C., Folláth, F., & Eichelbaum, M. F. (1986) · European Journal of Clinical Pharmacology · doi:10.1007/bf00870989 · Cited by 39
Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate
Siris, S. G., Cooper, T. B., Rifkin, A. E., et al. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.1.104 · Cited by 37
2‐Hydroxylation of ethinyloestradiol in relation to the oxidation of sparteine and antipyrine.
Back, D., Maggs, J. L., Purba, H., Newby, S., & Park, B. K. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02511.x · Cited by 18
Cited by
Newer antidepressants and the cytochrome P450 system
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.311 · Cited by 482
Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
Heim, M., & Meyer, U. A. (1990) · The Lancet · doi:10.1016/0140-6736(90)92086-w · Cited by 447
Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422
Self-citationInhibition and induction of human cytochrome P450 (CYP) enzymes
PELKONEN, O., MÄEENPÄEÄ, J., TAAVITSAINEN, P., RAUTIO, A., & RAUNIO, H. (1998) · Xenobiotica · doi:10.1080/004982598238886 · Cited by 358
Gender-related differences in pharmacokinetics and their clinical significance
Tanaka, E. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00246.x · Cited by 281
Metadata
- Authors
- Br�sen, K., & Gram, L. F.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 1989
- Volume
- 36
- Issue
- 6
- Pages
- 537-547
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2006744192
- Cited by
- 282
- References
- 38
- FWCI
- 20.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.